The antiretroviral-experienced patient

American Journal of the Medical Sciences

Volumn 328, Issue 1, 2004, Pages 10-16

  Clark, Rebecca A ^a,b   Wilcox, Ron ^a   Besch, C Lynn ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b HOP   (United States)

Author keywords

Antiretroviral experienced patient; Antiretroviral treatment failure; Structured treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LYMPHOCYTE COUNT; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PHENOTYPE; PRACTICE GUIDELINE; REVIEW; TREATMENT FAILURE; VIRUS LOAD;

EID: 3242685262     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200407000-00003     Document Type: Article

References (36)

1. Report of the NIH Panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998;47(RR-5):1-41.
2. Ho DD. Toward HIV eradication or remission: the tasks ahead. Science 1998;280:1866-7.
3. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-300.
4. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.
5. Ortiz GM, Nixon DF, Trkola A, et al. HIV-1 Specific immune responses in subjects who temporarily contain viral replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999;104:R13-8.
6. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at http://AIDSinfo.nih.gov. Accessed November 10, 2003.
7. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
8. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353:863-8.
9. Sterne JAC, May M, Costagliola D, et al. Does it matter where you came from? Prognosis of patients starting potent therapy, according to initial response. Abstract #181. In Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, Mass, February, 2003.
10. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 2001;15:1369-77.
11. Harrington M, Carpenter CC. Hit HIV-1 hard, but only when necessary. Lancet 2000;355:2147-52.
12. Bonfanti P, Valsecchi L, Parazzini F, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. J Acquir Immune Defic Syndr 2000;23:236-45.
13. Le Moing V, Chene G, Leport C, et al. Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients. Clin Infect Dis 2002;34:239-47.
14. Monforte AD, Lepri AC, Rezza G, et al. Insights into the reason for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral-naive patients. I. C. O. N. A. Study Group. Itialina Cohort of Antiretorivral-Naïve Patients. AIDS 2000;14:499-507.
15. Bonfanti P, Valsecchi L, Parazzini F, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitor: a cohort study. J Acquir Immune Defic Syndr 2001;26:191-3.
16. Dorrucci M, Pezzotti P, Grisorio B, et al. Time to discontinuation of the first highly active antiretroviral therapy regimen; a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. AIDS 2001;15:1733-6.
17. O'Brien M, Besch L, Clark RA, et al. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003;34:407-14.
18. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344:984-95.
19. Washington CB, Duran GE, Man MC, et al. Interactions of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:2023-9.
20. Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998;19:203-9.
21. Benet LZ, Izumi T, Zhang Y, et al. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral delivery. J Control Release 1999;62:25-31.
22. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996;2:760-6.
23. Acosta EP, Henry K, Kaken L, et al. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999;19:708-12.
24. Acosta EP, Gerber JG. Adult Pharmacology Committee of the AIDS Clinical Trials Group. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses, 2002;18:825-34.
25. Wilson JW. Update on antiretroviral drug resistance testing: combining laboratory technology with patient care. AIDS Reader 2003;13:25-38.
26. Kuritzkes DR. Perspectives: drug resistance testing in the management of antiretroviral therapy. Topics HIV Med 2001;9:10-4.
27. D'Aquila RT, Schapiro JM, Brun-Vezinet F, et al. Drug resistance mutations in HIV-1. Topics HIV Med 2002;10:11-6.
28. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000;283:2417-26.
29. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001;15:309-20.
30. Lawrence J, Mayers DL, Hullsiek K, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003;349:837-46.
31. Kaufmann D, Pantaleo G, Sudre P, et al. A CD4-cell count in HIV-1-infected individuals remaining viremic with highly active antiretroviral therapy (HAART): Swiss HIV Cohort Study. Lancet 1998;351:723-4.
32. Deeks SG, Wrin T, Ligler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001;344:472-80.
33. Deeks SG. When to switch antiretroviral therapy. (Abstract #188). 10th Conference on Retroviruses and Opportunistic Infections, Boston, Mass, February 10-14, 2003.
34. Deeks SG, Barbour JD, Grant RM, et al. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002;16:201-7.
35. Miller V, Phillips AN, Clotet B, et al. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002;186:189-97.
36. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85.